From the Departments of Imaging (H.P., M.N.) and Medical Oncology (M.M.A.), Dana-Farber Cancer Institute, and Departments of Radiology (H.P., H.H., M.N.), Pathology (L.M.S.), and Medicine (M.M.A.), Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA 02215.
Radiology. 2019 Oct;293(1):15-29. doi: 10.1148/radiol.2019190173. Epub 2019 Aug 6.
Advances in characterization of molecular and genomic abnormalities specific to lung cancer have made precision therapy the current standard of care for lung cancer treatment. This article will provide a cutting-edge review of imaging of lung cancer in the current era of precision medicine. The focus of the article includes an update on the recent advances in precision therapy for non-small cell lung cancer and their implications on imaging; molecular and genomic biomarkers and pitfalls of image interpretations for lung cancer precision therapy; and review of the current approaches and future directions of precision imaging for lung cancer, emphasizing emerging observations in longitudinal tumor kinetics, radiomics, and molecular and functional imaging. The article is designed to help radiologists to remain up to date in the rapidly evolving world of lung cancer therapy and serve as key members of multidisciplinary teams caring for these patients.
肺癌分子和基因组特征的研究进展使精准治疗成为当前肺癌治疗的标准。本文将对精准医学时代肺癌的影像学进行综述。文章的重点包括：介绍非小细胞肺癌精准治疗的最新进展及其对影像学的影响；分子和基因组生物标志物以及肺癌精准治疗中影像学解读的误区；综述肺癌精准成像的当前方法和未来方向，强调纵向肿瘤动力学、放射组学以及分子和功能成像方面的新观察。本文旨在帮助放射科医生跟上肺癌治疗领域快速发展的步伐，使他们成为多学科团队中治疗这些患者的关键成员。
